Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Repigel
- Development stage
- Phase 2
- Lead developer
- Mundipharma Research
- Modality
- Small Molecules, Hydrogel Systems → Drug Delivery Systems
- Administration
- Topical
01
Overview
Repigel is a 3% liposomal povidone-iodine hydrogel. It is being investigated for its antiseptic properties, primarily for the treatment of inflammatory acne by targeting and eliminating *Proprionibacterium Acnes*, and for managing infected mesh skin grafts by reducing bacterial load and promoting re-epithelialization. The formulation is designed to be cosmetically acceptable, becoming colorless and odorless shortly after topical application. In some regions, it is classified as a medicated device.
- Brand names
- RepithelRepiGel
- Other names
- PVP-ILH3% liposomal povidone-iodine hydrogel
Beyond the preview
Go deeper on Repigel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Repigel.